Avacta Group PLC (AIM:AVCT) Avacta Therapeutics Division Science Day

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is today holding a Science Day, focused on its Therapeutics Division, for institutional investors and analysts as stated in the announcement on the 19 December 2022.

No material new information will be disclosed as part of this meeting.

The event will include a detailed review of the ongoing ALS-6000-101 Phase 1a clinical trial of AVA6000, Avacta’s lead pre|CISION™ tumour targeted form of the chemotherapy drug Doxorubicin, in soft tissue sarcoma, as well as an update on preclinical programmes.

There will also be presentations from two outstanding key opinion leaders in the field of oncology, Professor Krishna Komanduri Chief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, University of California San Francisco, USA and Dr William Tap Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA

A copy of the presentations given at the Science Day will be made available on the Group’s website, along with a full recording of the day, within 24 hours of the end of the meeting.


For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director

Tel: +44 (0) 1904 21 7070


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.